{
  "id": 28141,
  "title": "Capricor Duchenne cell therapy voted down by FDA panel",
  "url": "https://urgent.news/2026/07/29/capricor-duchenne-cell-therapy-voted-down-by-fda-panel",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-07-29T21:31:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/capricor-fda-vote-deramiocel-duchenne-cardiomyopathy/826465/"
  },
  "original_language": "en",
  "account": null,
  "summary": "At a contentious meeting with possible implications for other rare disease drugmakers, outside experts ultimately determined that Capricor didn't prove deramiocel's benefits in Duchenne-related cardiomyopathy.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 4,
    "also_reported_by": [
      {
        "outlet": "STAT News",
        "title": "STAT+: FDA expert committee votes in favor of Replimune’s melanoma treatment",
        "url": "https://urgent.news/2026/07/30/stat-fda-expert-committee-votes-in-favor-of-replimunes-melanoma",
        "published": "2026-07-30T10:00:00.000Z"
      },
      {
        "outlet": "Endpoints News",
        "title": "Replimune scores win as FDA advisors back melanoma treatment",
        "url": "https://urgent.news/2026/07/30/replimune-scores-win-as-fda-advisors-back-melanoma-treatment",
        "published": "2026-07-30T19:11:21.000Z"
      },
      {
        "outlet": "BioPharma Dive",
        "title": "Replimune melanoma drug wins support of FDA panel",
        "url": "https://urgent.news/2026/07/30/replimune-melanoma-drug-wins-support-of-fda-panel",
        "published": "2026-07-30T21:25:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}